Senior Manager, Commercial Analytics & Business Intelligence
DBV Technologies
Summary
The Senior Manager, Commercial Analytics & Business Intelligence, is a pivotal, hands-on leader within the Commercial Operations function as DBV-Technologies prepares for its first U.S. commercial launch in Peanut Allergy. Reporting to the Head of Commercial Operations & Analytics, this individual will help design and build the commercial analytics engine from the ground up — the dashboards, data pipelines, KPIs, and insights that turn a first-launch biotech into a decision-ready organization.
Job description
In a first-launch environment, analytics is not a back-office reporting function — it is a core strategic capability. Every targeting decision, segmentation model, incentive plan, and performance review depends on trustworthy data and sharp interpretation. This role sits at the intersection of business strategy, advanced analytics, and commercial execution, serving as a key partner to Marketing, Sales Leadership, Market Access, Forecasting, Finance, and Executive Leadership.
Key Responsibilities
Analytics, Reporting & Performance Management
- Design, build, and maintain commercial analytics, reporting, dashboards, KPIs, and performance-management processes that give leadership a real-time view of launch performance against plan.
- Develop KPI scorecards, trend analyses, and variance reporting for business performance reviews with senior leadership.
- Translate complex, multi-source analyses into clear, actionable recommendations for executive decision-making.
Data Sources & Commercial Insights
- Develop insights from pharmaceutical patient, prescriber, claims, specialty pharmacy, hub, and market access data sources, integrating disparate feeds into coherent business narratives.
- Build and maintain the analytical layer connecting Xponent, LAAD, claims, specialty pharmacy/hub, and payer data into usable, trustworthy assets.
Launch Planning, Targeting & Field Effectiveness
- Support launch planning through HCP-level targeting, segmentation, and call-plan analytics that focus field resources where they matter most.
- Provide incentive compensation (IC) analytics and field force effectiveness measurement, quantifying the relationship between promotional activity and downstream prescribing.
- Evaluate targeting and segmentation model performance post-launch and recommend refinements based on observed results.
Forecasting, Finance & Scenario Analysis
- Partner with Forecasting and Finance to evaluate business scenarios, performance drivers, and resource-allocation trade-offs.
- Provide analytical support that connects performance data to budget cycles, long-range planning, and executive reporting.
Data Governance & Best Practices
- Drive data governance, documentation standards, and analytical best practices so the organization’s data assets are reliable, compliant, and reusable.
- Build scalable, automated pipelines and reporting to reduce manual effort and increase speed and accuracy.
AI & Advanced Analytics
- Identify high-value AI use cases and translate them into measurable business outcomes, applying LLMs, generative and agentic AI, and automation to improve commercial processes and decision-making.
- Apply traditional machine learning and statistical methods (predictive modeling, segmentation, propensity) where they add commercial value.
Requirements
- 8–10 years of progressive experience in pharmaceutical analytics, commercial operations, business intelligence, or a closely related field
- Advanced SQL proficiency, with the ability to write, optimize, and maintain complex queries against large commercial datasets
- Strong Python skills for data engineering, automation, analytics, and predictive modeling
- Hands-on experience with BI and visualization platforms such as Power BI, Tableau, or similar tools
- Demonstrated experience with pharmaceutical commercial datasets, including IQVIA Xponent, IQVIA LAAD, claims data, specialty pharmacy and hub data, market access / payer data, and HCP-level targeting and segmentation datasets
- Demonstrated success supporting pharmaceutical product launches, including targeting, segmentation, IC analytics, and field force effectiveness
- Exceptional executive communication and storytelling skills, with a proven ability to influence cross-functional stakeholders without formal authority
- Comfort operating in a fast-paced, ambiguous, prelaunch environment, balancing strategic thinking with hands-on execution
- Bachelor’s degree required, preferably in a quantitative discipline (Statistics, Economics, Mathematics, Engineering, Life Sciences, or related field)
- Experience supporting specialty, immunology, allergy, rare disease, or biologic product launches
- Familiarity with cloud-based analytics environments and modern data architectures (e.g., AWS, Azure, Databricks, Snowflake)
- Experience applying AI within commercial pharmaceutical organizations — including LLMs, generative AI, agentic AI, and automation tooling
- Experience with statistical analysis, predictive analytics, and data science methodologies
- Experience within emerging biotech companies or resource-constrained, high-growth environments
- Advanced degree (MBA, MS, or PhD) in a quantitative or business discipline
Company overview
DBV Technologies is a global clinical-stage biopharmaceutical company pioneering epicutaneous immunotherapy (EPIT) through its innovative Viaskin™ patch technology platform. Founded by pediatricians in 2002, the company is dedicated to developing safe and effective treatments for food allergies and immunologic diseases with significant unmet medical needs. DBV's core technology involves delivering biologically active compounds through intact skin to re-educate the immune system, offering a non-invasive alternative to traditional allergy treatments. The company's primary focus is on developing the Viaskin peanut patch for pediatric patients with peanut allergy, with ongoing Phase 3 clinical trials across different age groups. Headquartered in Châtillon, France, with operations in Warren, New Jersey, DBV maintains a global presence and is publicly traded on Euronext Paris and Nasdaq. The company's pipeline also includes programs for cow's milk allergy, eosinophilic esophagitis, autoimmune disorders, and vaccine applications, demonstrating the broad potential of its patch-based immunotherapy platform.